

Intermediate AMD Market Expected to Expand Significantly, 2024-2034 Report by DelveInsight

Exploring the Role of Novartis and Allegro Ophthalmics in Advancing Intermediate AMD Therapies

LAS VEGAS , NV, UNITED STATES, December 4, 2024 /EINPresswire.com/ -- DelveInsight's "Intermediate AMD Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Intermediate AMD, historical and forecasted epidemiology, and Intermediate AMD market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Unlock detailed insights into the Intermediate AMD market trends, treatments, and epidemiology by clicking here: [Intermediate AMD Market Forecast Report](#).

Key Facts and Analysis of the Intermediate AMD Market Report:

In 2023, the total Intermediate AMD market size in the 7MM was approximately USD 990 million, and growth is expected through 2024-2034.

The US had the highest prevalence of intermediate AMD cases in 2023, with around 19.9 million cases, expected to rise.

In Japan, intermediate AMD was most prevalent in the 65-84 age group, accounting for over 45% of cases in 2023.

AMD is a leading cause of vision loss in people over 60, with intermediate AMD being a key risk for progression to advanced stages.

Key companies in the market include Novartis, Allegro Ophthalmics, and others.

Key therapies include Iptacopan (LNP023), Ranibizumab, and Risuteganib (ALG-1001).

In November 2024, the FDA approved LumiThera's Valeda Light Delivery System for dry AMD.

The intermediate AMD market is expected to grow steadily, driven by awareness and new treatment options.

Intermediate AMD Overview

Intermediate AMD is a pivotal stage in the progression of age-related macular degeneration, often showing minimal or no symptoms. At this stage, individuals may experience distorted vision or central visual field loss, with a significant risk of progression to advanced AMD. Current

standard care focuses on monitoring visual function using tools like the Amsler grid. While treatment options remain limited, ongoing research is exploring innovative therapies, such as risuteganib. Early detection and proactive management are crucial in preventing irreversible vision loss, making continued research essential to overcome the challenges of intermediate AMD.

Intermediate AMD Epidemiology

The epidemiology chapter of the Intermediate AMD report offers a detailed analysis of both historical and forecasted data, segmented by total prevalent cases, diagnosed prevalent cases, and age-specific cases of Intermediate AMD. It covers the 7MM market, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, providing insights from 2020 to 2034. This comprehensive breakdown helps stakeholders understand the disease's trends and its evolving impact across key regions.

Intermediate AMD Epidemiology Segmentation

The Intermediate AMD market report provides an epidemiological analysis for the period 2020–2034 across the 7MM, segmented by:

Total Prevalent Cases

Total Diagnosed Prevalent Cases

Age-specific Cases

Intermediate AMD Pipeline Development Activities

The drug chapter of the Intermediate AMD report provides an in-depth analysis of pipeline drugs in mid-stage development (Phase II/III and Phase II). It highlights key players in the emerging drug landscape, including Novartis (Iptacopan) and Allegro Ophthalmics (Risuteganib). This section also offers valuable insights into clinical trial details, pharmacological actions, partnerships and collaborations, approval statuses, patent information, as well as the latest news and press releases, offering a comprehensive understanding of the evolving treatment landscape for intermediate AMD.

Intermediate AMD Therapies and Key Companies

Iptacopan (LNP023): Novartis

Risuteganib (ALG-1001): Allegro Ophthalmics

Explore the top therapies shaping the future of Intermediate AMD treatment at [Intermediate AMD Treatment Landscape](#).

Scope of the Intermediate AMD Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Intermediate AMD Companies: Novartis, Allegro Ophthalmics, and others.

Key Intermediate AMD Therapies: Iptacopan (LNP023), Ranibizumab, and Risuteganib (ALG-1001), and others.

Intermediate AMD Therapeutic Assessment: Intermediate AMD current marketed and Intermediate AMD emerging therapies

Intermediate AMD Market Dynamics: Intermediate AMD market drivers and Intermediate AMD market barriers.

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Intermediate AMD Unmet Needs, KOL's views, Analyst's views, Intermediate AMD Market Access and Reimbursement

Table of Contents

1. Intermediate AMD Market Report Introduction
2. Executive Summary for Intermediate AMD
3. SWOT analysis of Intermediate AMD
4. Intermediate AMD Patient Share (%) Overview at a Glance
5. Intermediate AMD Market Overview at a Glance
6. Intermediate AMD Disease Background and Overview
7. Intermediate AMD Epidemiology and Patient Population
8. Country-Specific Patient Population of Intermediate AMD
9. Intermediate AMD Current Treatment and Medical Practices
10. Intermediate AMD Unmet Needs
11. Intermediate AMD Emerging Therapies
12. Intermediate AMD Market Outlook
13. Country-Wise Intermediate AMD Market Analysis (2020–2034)
14. Intermediate AMD Market Access and Reimbursement of Therapies
15. Intermediate AMD Market Drivers
16. Intermediate AMD Market Barriers
17. Intermediate AMD Appendix
18. Intermediate AMD Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Report:

[Intermediate AMD Epidemiology Report](#)

DelveInsight's "Intermediate AMD – Epidemiology – 2034" report provides a thorough analysis of Intermediate AMD, offering historical and forecasted epidemiological data for the condition across key regions, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. This report delivers valuable insights into the prevalence, incidence, and demographics of Intermediate AMD, helping stakeholders better understand the disease's impact and trends through 2034.

About DelveInsight

DelveInsight is a prominent consulting and market research firm in the healthcare sector. It specializes in providing comprehensive end-to-end solutions to pharmaceutical companies. Its services aim to enhance the performance of pharmaceutical businesses by offering strategic insights, data-driven analysis, and actionable recommendations.

Their expertise extends to healthcare consulting services, where they assist in market analysis, enabling companies to navigate challenges and drive business growth. By focusing on the life sciences industry, DelveInsight helps organizations make informed decisions, optimize their operations, and accelerate success in a competitive market.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/766080436>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.